HomeCompareAZYO vs EQR

AZYO vs EQR: Dividend Comparison 2026

AZYO yields 134.23% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AZYO wins by $14.38M in total portfolio value
10 years
AZYO
AZYO
● Live price
134.23%
Share price
$1.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.42M
Annual income
$5,849,084.49
Full AZYO calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — AZYO vs EQR

📍 AZYO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZYOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZYO + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZYO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZYO
Annual income on $10K today (after 15% tax)
$11,409.40/yr
After 10yr DRIP, annual income (after tax)
$4,971,721.82/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, AZYO beats the other by $4,968,475.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZYO + EQR for your $10,000?

AZYO: 50%EQR: 50%
100% EQR50/50100% AZYO
Portfolio after 10yr
$7.23M
Annual income
$2,926,452.05/yr
Blended yield
40.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AZYO
Analyst Ratings
4
Buy
Consensus: Buy
Price Target
$10.25
+587.9% upside vs current
Range: $10.00 — $10.50
Altman Z
-3.7
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZYO buys
0
EQR buys
0
No recent congressional trades found for AZYO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZYOEQR
Forward yield134.23%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$14.42M$40.5K
Annual income after 10y$5,849,084.49$3,819.61
Total dividends collected$13.23M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$10.25$70.35

Year-by-year: AZYO vs EQR ($10,000, DRIP)

YearAZYO PortfolioAZYO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$24,123$13,422.82$11,248$547.57+$12.9KAZYO
2$56,073$30,261.33$12,701$666.53+$43.4KAZYO
3$125,738$65,739.74$14,405$814.59+$111.3KAZYO
4$272,310$137,770.90$16,413$999.84+$255.9KAZYO
5$570,223$278,851.11$18,795$1,232.92+$551.4KAZYO
6$1,155,858$545,719.55$21,639$1,527.95+$1.13MAZYO
7$2,270,590$1,033,821.54$25,057$1,903.80+$2.25MAZYO
8$4,327,530$1,897,998.85$29,197$2,385.87+$4.30MAZYO
9$8,011,211$3,380,754.03$34,250$3,008.70+$7.98MAZYO
10$14,421,080$5,849,084.49$40,467$3,819.61+$14.38MAZYO

AZYO vs EQR: Complete Analysis 2026

AZYOStock

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Full AZYO Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this AZYO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZYO vs SCHDAZYO vs JEPIAZYO vs OAZYO vs KOAZYO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.